HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Longitudinal analysis of retinal hemangioblastomatosis and visual function in ocular von Hippel-Lindau disease.

AbstractOBJECTIVE:
Characterization of the structural and functional progression of ocular von Hippel-Lindau (VHL) disease and analysis of patient factors influencing disease progression.
DESIGN:
Retrospective analysis of a case series from a longitudinal, observational study.
PARTICIPANTS:
Two hundred forty-nine participants with clinically defined systemic VHL disease and more than 2 years of ophthalmic follow-up.
METHODS:
Standardized scoring of ocular phenotype and systemic characteristics was performed at each study visit and was analyzed longitudinally to determine progression of ocular VHL disease.
MAIN OUTCOME MEASURES:
Measures evaluated include: visual acuity, features of ocular VHL disease (presence, location, number, and extent of retinal capillary hemangioblastomas [RCHs]), germline mutation in the VHL gene, demographics (age, gender, age at onset of ocular disease), and patient characteristics (smoking status, body mass index).
RESULTS:
Most participants demonstrated relative anatomic and functional stability in ocular VHL disease status over a mean follow-up of 8.2 ± 4.0 years. Approximately three quarters (73%) of participants without ocular VHL disease at baseline remained disease free at the end of follow-up. Among eyes with ocular VHL disease at baseline, 88% did not demonstrate RCHs in a new retinal location, 70% remained stable in RCH number, and 79% remained stable in the extent of RCH involvement. Mean visual acuity for all study eyes (n = 498) decreased by 5.1 ± 0.6 letters across follow-up, with 16.1% of study eyes decreasing by more than 10 letters in visual acuity. Among eyes affected at baseline, greater vision loss was associated with the presence of juxtapapillary RCHs, development of RCH in a new location, and increase in peripheral RCH number and extent. Younger baseline age, younger age at onset of ocular VHL disease, involvement of the fellow eye with ocular VHL disease, and missense or protein-truncating germline mutations were associated significantly with increased anatomic involvement and functional deterioration.
CONCLUSIONS:
Patients with ocular VHL disease maintain relative anatomic and functional stability, with only a minority demonstrating marked anatomic progression and vision loss. Systemic and ocular risk factors for anatomic progression and vision loss can help practitioners identify patients with a higher risk profile for counseling, closer follow-up, and proactive treatment.
FINANCIAL DISCLOSURE(S):
The author(s) have no proprietary or commercial interest in any materials discussed in this article.
AuthorsBrian C Toy, Elvira Agrón, Divya Nigam, Emily Y Chew, Wai T Wong
JournalOphthalmology (Ophthalmology) Vol. 119 Issue 12 Pg. 2622-30 (Dec 2012) ISSN: 1549-4713 [Electronic] United States
PMID22906772 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Von Hippel-Lindau Tumor Suppressor Protein
  • VHL protein, human
Topics
  • Adult
  • Disease Progression
  • Female
  • Germ-Line Mutation
  • Hemangioblastoma (genetics, physiopathology)
  • Humans
  • Longitudinal Studies
  • Male
  • Mutation
  • Retinal Neoplasms (genetics, physiopathology)
  • Retrospective Studies
  • Visual Acuity (physiology)
  • Von Hippel-Lindau Tumor Suppressor Protein (genetics)
  • von Hippel-Lindau Disease (genetics, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: